LSE - Delayed Quote GBp

Creo Medical Group PLC (CREO.L)

Compare
20.00 0.00 (0.00%)
At close: October 25 at 3:30 PM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
NameTitlePayExercisedYear Born
Mr. Craig Jonathan Gulliford CEO & Executive Director 585.75k -- 1970
Prof. Christopher Paul Hancock Founder, CTO & Executive Director 425.28k -- 1967
Mr. Richard John Rees ACA CFO & Executive Director 428.68k -- 1976
Mr. David Gerard Woods Chief Commercial Officer & Executive Director 478.46k -- 1965
Mr. Phil Hales Sales & Marketing Director -- -- --
Mr. Richard Gary Craven Secretary -- -- --

Creo Medical Group PLC

Creo House
Unit 2, Beaufort Park Beaufort Park Way
Chepstow, NP16 5UH
United Kingdom
44 12 9160 6005 https://www.creomedical.com
Sector:?
Healthcare
Industry:?
Medical Devices
Full Time Employees:?
278

Description

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the gastrointestinal (GI) tract; ScopeClip for clip placement in the digestive tract; ScopeInject for endoscopic injection into GI mucosa; ScoprGrasp, a disposable grasping forceps for digestive and bronchial endoscopy; ScopeBite, a portfolio of digestive biopsy forceps; and other products for gastroenterology, pulmonology, and urology. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.

Corporate Governance

Creo Medical Group PLC’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

September 30, 2024 at 2:46 PM UTC

Creo Medical Group PLC Earnings Date

Recent Events

Related Tickers